Bifidobacterium Breve Yang08 Alleviates Atopic Dermatitis By Enriching Akkermansia Muciniphila and Inhibiting Neutrophil Extracellular Traps Formation In Mice.

2026-02-08
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 13(20)
- Yanqiang Shi
- Shuang He
- Chengyi Li
- Hung Chan
- Zhenfeng Liu
- Bin Yang
- Qing Li

PubMed: 41655253
DOI: 10.1002/advs.202518588

Atopic dermatitis (AD) is linked to gut microbiota dysbiosis, yet the mechanisms connecting specific commensals to cutaneous immunoregulation remain elusive. We observed reduced Bifidobacterium breve (B. breve) abundance in AD patients. A new B. breve strain was isolated from human stools and nomenclated as Yang08. In MC903-induced AD-like mouse models, Yang08 outperformed a standard strain, ameliorating disease severity, including reduced ear thickening, epidermal hyperplasia, and mast cell infiltration in a manner dependent on viable bacteria and an intact gut microbiota. Antibiotic-mediated microbiota depletion abrogated its efficacy, while fecal microbiota transfer from Yang08-treated mice conferred protection, confirming microbial remodeling as essential. Metagenomics revealed Yang08 specifically enriched Akkermansia muciniphila, which was required for therapeutic effects in germ-free mice. Mechanistically, Yang08 abolished both neutrophil influx and NET deposition in lesions, with ex vivo experiments showing blunted NETosis capacity. Its therapeutic benefits were reversed by neutrophil depletion, NET degradation, or PAD4 inhibition. Overall, Yang08 alleviates AD by enriching A. muciniphila and inhibiting skin NETosis, emerging as a promising prophylactic candidate prevention for AD prevention.

Research Insights

Supplement	Health Outcome	Effect Type	Effect Size
Bifidobacterium breve	Reduced Atopic Dermatitis Severity	Beneficial	Large
Bifidobacterium breve	Reduced Neutrophil Extracellular Trap Formation	Beneficial	Large
Bifidobacterium breve	Restored Gut Microbiota	Beneficial	Moderate